ライフサイエンスコーパス: noncompliance

1 not listed or removed from the list based on noncompliance).

2 n lost due to acute or chronic rejection and noncompliance).

3 essants that frequently results in treatment noncompliance.

4 sis, and one of severe depression leading to noncompliance.

5 dialysis, because of renal allograft loss to noncompliance.

6 iance, was predictive of posttransplantation noncompliance.

7 oup of patients, who are clearly at risk for noncompliance.

8 entions and educational programs to minimize noncompliance.

9 e agents considered a significant reason for noncompliance.

10 ting bioavailability limitations and patient noncompliance.

11 9 caregivers to determine factors related to noncompliance.

12 g psychotic and affective relapse as well as noncompliance.

13 FK group was because of acknowledged patient noncompliance.

14 on achieved by delivery of compressed air on noncompliance.

15 ration can be difficult owing to age-related noncompliance.

16 6% of mothers, all resulting from medication noncompliance.

17 One patient of group 3 lost graft to noncompliance.

18 0.91; P=0.001), and 29% after adjustment for noncompliance.

19 f financial factors, such as co-payments, on noncompliance.

20 f 13 rejection episodes were associated with noncompliance.

21 lcium salts, which may contribute to patient noncompliance.

22 asis for developing interventions to curtail noncompliance.

23 fficult to identify the impact of medication noncompliance.

24 of strategies that are helpful in mitigating noncompliance.

25 pport services, can lessen the occurrence of noncompliance.

26 e contributed in large measure to medication noncompliance.

27 obtain adjusted relative risks of household noncompliance.

28 tes increased the relative risk of household noncompliance (1.32).

29 y (57%), lack of available trials (41%), and noncompliance (2%).

30 val than choice of therapy (hazard ratio for noncompliance=2.79; 95% confidence limits, 2.19-3.54; P<

31 Finally, many residents report noncompliance (67.6%) and duty hour falsification (62.1%

32 R (16% vs. 0.3%, P<0.001), an AR ascribed to noncompliance (8% vs. 2%, P=0.001), and a recurrent AR (

33 ine as the primary outcome and adjusting for noncompliance, a study of subjects with Stage II chronic

34 tigated variables associated with medication noncompliance after renal transplantation.

35 may play a future critical role in avoiding noncompliance, although optimizing renal function and gr

36 l is to determine the impact of hand hygiene noncompliance among peripatetic (eg, highly mobile or hi

37 patitis C virus group due to higher rates of noncompliance, an effect that disappears with censoring

38 The combination of medication noncompliance and alcohol or substance abuse problems wa

39 because of concern about possible increased noncompliance and allegedly inferior long-term results.

40 other socioeconomic variables contributed to noncompliance and allograft survival.

41 sing a sample size formula that incorporates noncompliance and assumes that a certain proportion of s

42 consensus that a relationship exists between noncompliance and clinical outcomes in health care, incl

43 simulation showed that after correcting for noncompliance and contamination, there is potential bene

44 n inconsistent, due partly to differences in noncompliance and contamination.

45 ransplantation are associated with increased noncompliance and graft loss.

46 Identifying predictors of noncompliance and initiating preventive strategies, incl

47 s, provide opportunities to study medication noncompliance and its risk factors, and the potential fo

48 domized trials should address issues of both noncompliance and missing data.

49 and lack of pulmonary selectivity result in noncompliance and poor patient outcomes.

50 We summarize previous studies of noncompliance and report results of a large, multicenter

51 Dietary noncompliance and smoking were each associated with odds

52 sally initiated; however, treatment failure, noncompliance and subtherapeutic dosing were often repor

53 isruption in treatment because of medication noncompliance and the appearance of mixed episodes and r

54 bsequent to kidney failure, one secondary to noncompliance and the other as a result of hemolytic-ure

55 beta-Blocker noncompliance and use of QT-prolonging drug are responsi

56 patients' attitudes when evaluating risks of noncompliance and when developing interventions and educ

57 are highly sensitive to levels of systematic noncompliance and, in many settings, it will lead to an

58 Late noncompliance and/or rejection in African Americans with

59 ption, rehospitalization, immunosuppression, noncompliance, and a greater risk of graft loss and deat

60 rrent stroke on transfusions, iron overload, noncompliance, and deferoxamine allergy.

61 Issues related to subject attrition, noncompliance, and individual differences in treatment r

62 ee died in remission; 16 withdrew because of noncompliance, and nine withdrew with toxicity.

63 c status, poor premorbid function, treatment noncompliance, and substance abuse were associated with

64 esses of specific pharmacotherapies, such as noncompliance, and thus can play a substantial role in b

65 and due process to an individual accused of noncompliance; and 3) ensuring compliance with federal r

66 vanced visual field loss at presentation and noncompliance are risk factors for development of blindn

67 We then compared the effects of hand hygiene noncompliance as a function of connectedness.

68 upply type was significantly associated with noncompliance at the source (p < 0.001) and in HSW (p =

69 The mean percentage of contaminated samples (noncompliance) at the source was 46% (95% CI: 33, 60%),

70 olymorphisms (CYP2C19, CYP3A5, ABCB1, PON1), noncompliance, co-medications, diet, smoking, alcohol, d

71 pecific adjusted relative risks of household noncompliance compared with Texas were 2.14 (Michigan),

72 imator analogous to ones previously used for noncompliance corrections in randomized clinical trials.

73 e that takes account of prolonged periods of noncompliance distinguished between the treatments and w

74 Patient noncompliance, drug interactions, and pregnancy can lead

75 acute rejection is uncommon, and medication noncompliance emerges as an increasingly important facto

76 y also compared frequencies of side effects, noncompliance episodes, and subsyndromal symptomatic fla

77 sus on the incidence of graft failure-due-to noncompliance (GFNC), with some reporting it as relative

78 oeconomic variables including low income and noncompliance impact negatively upon long-term renal all

79 ence of patient CINE experience coupled with noncompliance improved results.

80 Odds were highest for dietary noncompliance in combination with smoking (odds ratio: 3

81 ergy intake term accounting for intermittent noncompliance in dietary intake to reach this plateau.

82 urce was 46% (95% CI: 33, 60%), whereas mean noncompliance in HSW was 75% (95% CI: 64, 84%).

83 This may, in turn, lead to noncompliance in misguided efforts to retain satisfactor

84 nts that (1) is caused by underdosing and/or noncompliance in only approximately 2% of patients and (

85 Medication noncompliance in teenagers has been shown to be more tha

86 ecommendation offered no specific reason for noncompliance; insurance was a barrier in a minority.

87 ed and dealt with, because studies show that noncompliance is a "stable" personality attribute that p

88 Because noncompliance is associated with worse outcomes, future

89 Noncompliance is much more common in US patients undergo

90 es have clearly demonstrated that medication noncompliance leads to an increased incidence of acute r

91 The noncompliance logistic regression model including patien

92 A noncompliance model composed of only patient and transpl

93 ocol at reduced immunosuppression because of noncompliance (n=8), recurrent PBC (n=2), pregnancy (n=1

94 hment with vitreomacular traction in 3 eyes, noncompliance of native internal limiting membrane in 2

95 he restricted substrate scope, in particular noncompliance of unactivated aliphatic olefins, has disc

96 Parents rated disruptive behavior and noncompliance on co-primary outcomes: the Aberrant Behav

97 reported literature, the clinical impact of noncompliance on recurrence severity and mortality are n

98 int effect of substance abuse and medication noncompliance on the greater risk of serious violence am

99 dditional patients were withdrawn because of noncompliance; one of them later required liver transpla

100 Physicians may mistake either medication noncompliance or lack of persistency with poor efficacy.

101 gastrointestinal symptoms (29%), medication noncompliance or lost to followup (14%), and elevated li

102 Nine patients were not evaluable because of noncompliance or taking concomitant vasoactive medicatio

103 or renal transplantation included history of noncompliance (OR=0.17, CI 0.13, 0.23), <25% cardiac eje

104 ents because of life-threatening infections, noncompliance, or both.

105 ase, acute rejection, thrombosis, infection, noncompliance, or technical problems.

106 either drug; 23 were excluded (single visit, noncompliance, or therapy < 1 week), leaving 95 patients

107 animal welfare considerations in developing noncompliance policies and procedures for institutional

108 nt was similar in the 2 groups; however, the noncompliance rate was high (35% of all enrollees).

109 Noncompliance rates of at least 25% commonly have been r

110 common problems (e.g., attrition, medication noncompliance, reduction of error variance, and ethical

111 The incidence of noncompliance reported by the 1402 respondents was 22.4%

112 and 1.16 (95% CI, 0.86-1.56) for partial or noncompliance, respectively.

113 Patient noncompliance seemed responsible for 45% (13/29) of obse

114 cipients do not seem to have higher rates of noncompliance than D recipients.

115 Underperformance depended less on medical noncompliance than with systematic features of the metho

116 study visits (P = 0.046) were predictors of noncompliance; their odds ratios and confidence interval

117 elines and determine factors associated with noncompliance to these guidelines.

118 worse than reported in clinical trials, and noncompliance translated into a significant increase in

119 Mortality from chronic rejection and noncompliance under tacrolimus has been exceedingly rare

120 These include noncompliance, vascular access recirculation, and dialyz

121 The mean per-patient noncompliance was 13.1% (95% CI, 7.8-25.4) of those assi

122 in samples following WSP implementation and noncompliance was also significantly reduced (p < 0.001

123 In all scenarios, noncompliance was corrected using incidence and survival

124 Noncompliance was defined as missing 2 or more study vis

125 Guideline noncompliance was most prominent in patients with minor

126 Graft loss due to noncompliance was significantly more common after psycho

127 Noncompliance was the third most common cause of death,

128 Noncompliance with adjuvant hormonal therapy among women

129 r carcinoma recurrence, and those at risk of noncompliance with antiviral therapy.

130 ithms were effective in offsetting potential noncompliance with deworming treatments for 16,357 indiv

131 Noncompliance with drug therapy, homelessness, immigrati

132 appropriate consideration of allegations of noncompliance with federal Animal Welfare Act regulation

133 are widely available, 2) correct bias due to noncompliance with fixed or dynamic treatment regimens,

134 Noncompliance with follow-up recommendations is an impor

135 o an aggressive, 3-hour sepsis bundle versus noncompliance with greater than or equal to one bundle e

136 One patient died of graft dysfunction, noncompliance with immunosuppressant medications, and pr

137 nt recipients were excluded because of known noncompliance with immunosuppressive medication, leaving

138 Noncompliance with immunosuppressive medications after r

139 sion models (sets of variables) that predict noncompliance with immunosuppressive regimens.

140 of severe acute rejection despite continuous noncompliance with immunosuppressive therapy.

141 racteristic risk-taking behaviors, including noncompliance with medical treatments.

142 Noncompliance with medication is a major cause of renal

143 Because noncompliance with medication regimens is a major cause

144 icide attempts, history of mental illness or noncompliance with medications) is advisable early in th

145 only 1 was attributed to recidivism and 3 to noncompliance with recidivism.

146 Noncompliance with recognized standards and poor aseptic

147 Noncompliance with results of RDT tests is relatively ra

148 The relatively high rate of noncompliance with short-interval follow-up recommendati

149 ine patient characteristics that may predict noncompliance with study visits (disease duration, disea

150 cedures for the management of allegations of noncompliance with the Animal Welfare Act and the U.S. P

151 i clubfoot program are primarily poverty and noncompliance with the extended post-casting brace proto

152 examined as possible contributing factors to noncompliance with the relationship.

153 vanced visual field loss at presentation and noncompliance with the treatment regimen.

154 y the additional toxic effects and potential noncompliance with their long-term administration?

155 Noncompliance with therapeutic diets remains a major obs

156 Patient noncompliance with therapy is a major reason for poor as

157 ty-hour standards, interns commonly reported noncompliance with these requirements.

158 Within the ventilation protocol, noncompliance with tidal volume and plateau pressure tar

159 A mismatches, lower levels of education, and noncompliance with transplant medications and follow-up

160 c graft loss in our population is related to noncompliance with transplant medications, which occurre

161 mental health care specialist due to stigma, noncompliance with treatment, and lack of health insuran

162 supplementary immunization activities due to noncompliance with vaccination recommendations, a rise i

163 d 90 and fewer ventilator-free days, whereas noncompliance with weaning guideline was only associated

164 5 years; losses were due to nephropathy and noncompliance, with 1 death with function.